Table 1.
Baseline demographic and clinical characteristics of patients enrolled in this study results reported as N (%), unless otherwise indicated
| Characteristic | TACE plus sorafenib (n=80) | TACE alone (n=76) |
| Age, median (range), years | 72.0 (36–85) | 73.0 (53–86) |
| Sex | ||
| Male | 63 (78.8) | 55 (72.4) |
| Female | 17 (21.2) | 21 (27.6) |
| Performance status | ||
| 0 | 71 (88.8) | 67 (88.2) |
| 1 | 9 (11.3) | 9 (11.8) |
| Aetiology | ||
| Hepatitis B | 10 (12.5) | 2 (2.6) |
| Hepatitis C | 38 (47.5) | 53 (69.7) |
| Non-B Non-C | 32 (40.0) | 21 (27.6) |
| Child-Pugh score | ||
| 5 | 64 (80.0) | 54 (71.1) |
| 6 | 15 (18.8) | 17 (22.4) |
| 7 | 1 (1.3) | 5 (5.6) |
| Ascites | 0 (0) | 0 (0) |
| Treatment with diuretics | 10 (12.5) | 9 (11.8) |
| AFP | ||
| <200 ng/mL | 64 (80.0) | 60 (78.9) |
| ≥200 ng/mL | 16 (20.0) | 16 (21.1) |
| Tumour burden | ||
| Within Milan criteria | 28 (35.0) | 35 (46.1) |
| Outside Milan criteria | 52 (65.0) | 41 (53.9) |
| Up to T7 criteria | ||
| Within | 54 (67.5) | 50 (65.8) |
| Outside | 26 (32.5) | 26 (34.2) |
| BCLC stage | ||
| A | 27 (33.8) | 33 (43.4) |
| B | 44 (55.0) | 34 (44.7) |
| C | 9 (11.3) | 9 (11.8) |
| Prior TACE | ||
| 0 | 45 (56.3) | 48 (63.2) |
| 1–2 | 35 (43.8) | 28 (36.8) |
BCLC, Barcelona Clinic Liver Cancer; TACE, transarterial chemoembolisation.